Yue Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yue Yang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Fei Li
The First Hospital of Jilin University, Changchun, Jilin, China
2 shared publications - Xiaoqin Liu
School of Nursing, Jilin University, Changchun, CN
2 shared publications - Xinting Zhang
Department of Neurotrauma Surgery, The First Hospital of Jilin University, Changchun, CN
2 shared publications - Yang Li
Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Jilin, China, Changchun, CN
2 shared publications - Chao Lv
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication - Hui Wang
Department of Maternal and Child Health, School of Public Health Peking University Beijing China
1 shared publication
Latest Publications
- Open Access
- 10 April 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e59579
Effectiveness of Telemedicine-Delivered Carbohydrate-Counting Interventions in Patients With Type 1 Diabetes: Systematic Review and Meta-Analysis
Background: Type 1 diabetes mellitus (T1DM) significantly affects patients’ quality of life and can be life-threatening, necessitating improved monitoring strategies. Telemedicine, which leverages telecommunications technologies to deliver health care services and expertise, has the potential to enhance T1DM management. However, its effectiveness remains to be fully established. Objective: This study aims to evaluate the effectiveness of various telemedicine-based carbohydrate-counting (CC) interventions in patients with T1DM. Methods: This systematic review and meta-analysis searched 5 databases—PubMed, Web of Science, CINAHL, Embase, and Cochrane—as well as reference lists of retrieved articles on September 26, 2024, for randomized controlled trials (RCTs) assessing the effectiveness of telemedicine-based CC interventions in reducing glycated hemoglobin A1c (HbA1c) levels in patients with T1DM. Results: From 3612 citations, we identified 18 eligible RCTs (n=1627) from 14 regions for inclusion in the meta-analysis. Participants in the telemedicine intervention group experienced a 0.35% reduction in HbA1c levels (95% CI –0.54 to –0.16) compared with the control group. A total of 13 studies used smartphone apps, 4 used connected and wearable glucometers, and 3 delivered the intervention through web-based systems. Significant reductions in HbA1c were observed across smartphone apps (–0.36%, 95% CI –0.63% to –0.09%), connected and wearable glucometers (–0.35%, 95% CI –0.56% to –0.14%), and web-based systems (–0.36%, 95% CI –0.71% to –0.02%). Considerable heterogeneity was noted (I2=81%, P<.001). Telemedicine-based CC interventions also increased time in range by 9.59% (95% CI 6.50%-12.67%). However, evidence regarding treatment satisfaction, total daily insulin dose, and hypoglycemia remains inconclusive. Subgroup analysis showed that telemedicine platform variety did not significantly contribute to heterogeneity, while meta-regression indicated that the impact on HbA1c was most pronounced in trials conducted in Asia. Conclusions: Compared with usual care, telemedicine-delivered CC interventions improved HbA1c and time in range but did not significantly impact other clinically relevant outcomes in patients with T1DM. High-quality, large-scale RCTs are needed to draw definitive conclusions. These findings provide health care professionals with updated evidence on the role of telemedicine in glycemic control for patients with T1DM. Trial Registration: PROSPERO CRD42024523025; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024523025
- 10 April 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e59579
Open AccessEffectiveness of Telemedicine-Delivered Carbohydrate-Counting Interventions in Patients With Type 1 Diabetes: Systematic Review and Meta-Analysis
Background: Type 1 diabetes mellitus (T1DM) significantly affects patients’ quality of life and can be life-threatening, necessitating improved monitoring strategies. Telemedicine, which leverages telecommunications technologies to deliver health care services and expertise, has the potential to enhance T1DM management. However, its effectiveness remains to be fully established. Objective: This study aims to evaluate the effectiveness of various telemedicine-based carbohydrate-counting (CC) interventions in patients with T1DM. Methods: This systematic review and meta-analysis searched 5 databases—PubMed, Web of Science, CINAHL, Embase, and Cochrane—as well as reference lists of retrieved articles on September 26, 2024, for randomized controlled trials (RCTs) assessing the effectiveness of telemedicine-based CC interventions in reducing glycated hemoglobin A1c (HbA1c) levels in patients with T1DM. Results: From 3612 citations, we identified 18 eligible RCTs (n=1627) from 14 regions for inclusion in the meta-analysis. Participants in the telemedicine intervention group experienced a 0.35% reduction in HbA1c levels (95% CI –0.54 to –0.16) compared with the control group. A total of 13 studies used smartphone apps, 4 used connected and wearable glucometers, and 3 delivered the intervention through web-based systems. Significant reductions in HbA1c were observed across smartphone apps (–0.36%, 95% CI –0.63% to –0.09%), connected and wearable glucometers (–0.35%, 95% CI –0.56% to –0.14%), and web-based systems (–0.36%, 95% CI –0.71% to –0.02%). Considerable heterogeneity was noted (I2=81%, P<.001). Telemedicine-based CC interventions also increased time in range by 9.59% (95% CI 6.50%-12.67%). However, evidence regarding treatment satisfaction, total daily insulin dose, and hypoglycemia remains inconclusive. Subgroup analysis showed that telemedicine platform variety did not significantly contribute to heterogeneity, while meta-regression indicated that the impact on HbA1c was most pronounced in trials conducted in Asia. Conclusions: Compared with usual care, telemedicine-delivered CC interventions improved HbA1c and time in range but did not significantly impact other clinically relevant outcomes in patients with T1DM. High-quality, large-scale RCTs are needed to draw definitive conclusions. These findings provide health care professionals with updated evidence on the role of telemedicine in glycemic control for patients with T1DM. Trial Registration: PROSPERO CRD42024523025; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024523025
- Open Access
- 16 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness of Telemedicine-Delivered Carbohydrate-Counting Interventions in Patients With Type 1 Diabetes: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Type 1 diabetes mellitus (T1DM) significantly affects patients’ quality of life and can be life-threatening, necessitating improved monitoring strategies. Telemedicine, which leverages telecommunications technologies to deliver health care services and expertise, has the potential to enhance T1DM management. However, its effectiveness remains to be fully established. OBJECTIVE This study aims to evaluate the effectiveness of various telemedicine-based carbohydrate-counting (CC) interventions in patients with T1DM. METHODS This systematic review and meta-analysis searched 5 databases—PubMed, Web of Science, CINAHL, Embase, and Cochrane—as well as reference lists of retrieved articles on September 26, 2024, for randomized controlled trials (RCTs) assessing the effectiveness of telemedicine-based CC interventions in reducing glycated hemoglobin A1c (HbA1c) levels in patients with T1DM. RESULTS From 3612 citations, we identified 18 eligible RCTs (n=1627) from 14 regions for inclusion in the meta-analysis. Participants in the telemedicine intervention group experienced a 0.35% reduction in HbA1c levels (95% CI –0.54 to –0.16) compared with the control group. A total of 13 studies used smartphone apps, 4 used connected and wearable glucometers, and 3 delivered the intervention through web-based systems. Significant reductions in HbA1c were observed across smartphone apps (–0.36%, 95% CI –0.63% to –0.09%), connected and wearable glucometers (–0.35%, 95% CI –0.56% to –0.14%), and web-based systems (–0.36%, 95% CI –0.71% to –0.02%). Considerable heterogeneity was noted (I2=81%, P<.001). Telemedicine-based CC interventions also increased time in range by 9.59% (95% CI 6.50%-12.67%). However, evidence regarding treatment satisfaction, total daily insulin dose, and hypoglycemia remains inconclusive. Subgroup analysis showed that telemedicine platform variety did not significantly contribute to heterogeneity, while meta-regression indicated that the impact on HbA1c was most pronounced in trials conducted in Asia. CONCLUSIONS Compared with usual care, telemedicine-delivered CC interventions improved HbA1c and time in range but did not significantly impact other clinically relevant outcomes in patients with T1DM. High-quality, large-scale RCTs are needed to draw definitive conclusions. These findings provide health care professionals with updated evidence on the role of telemedicine in glycemic control for patients with T1DM. CLINICALTRIAL PROSPERO CRD42024523025; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024523025
- 16 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness of Telemedicine-Delivered Carbohydrate-Counting Interventions in Patients With Type 1 Diabetes: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Type 1 diabetes mellitus (T1DM) significantly affects patients’ quality of life and can be life-threatening, necessitating improved monitoring strategies. Telemedicine, which leverages telecommunications technologies to deliver health care services and expertise, has the potential to enhance T1DM management. However, its effectiveness remains to be fully established. OBJECTIVE This study aims to evaluate the effectiveness of various telemedicine-based carbohydrate-counting (CC) interventions in patients with T1DM. METHODS This systematic review and meta-analysis searched 5 databases—PubMed, Web of Science, CINAHL, Embase, and Cochrane—as well as reference lists of retrieved articles on September 26, 2024, for randomized controlled trials (RCTs) assessing the effectiveness of telemedicine-based CC interventions in reducing glycated hemoglobin A1c (HbA1c) levels in patients with T1DM. RESULTS From 3612 citations, we identified 18 eligible RCTs (n=1627) from 14 regions for inclusion in the meta-analysis. Participants in the telemedicine intervention group experienced a 0.35% reduction in HbA1c levels (95% CI –0.54 to –0.16) compared with the control group. A total of 13 studies used smartphone apps, 4 used connected and wearable glucometers, and 3 delivered the intervention through web-based systems. Significant reductions in HbA1c were observed across smartphone apps (–0.36%, 95% CI –0.63% to –0.09%), connected and wearable glucometers (–0.35%, 95% CI –0.56% to –0.14%), and web-based systems (–0.36%, 95% CI –0.71% to –0.02%). Considerable heterogeneity was noted (I2=81%, P<.001). Telemedicine-based CC interventions also increased time in range by 9.59% (95% CI 6.50%-12.67%). However, evidence regarding treatment satisfaction, total daily insulin dose, and hypoglycemia remains inconclusive. Subgroup analysis showed that telemedicine platform variety did not significantly contribute to heterogeneity, while meta-regression indicated that the impact on HbA1c was most pronounced in trials conducted in Asia. CONCLUSIONS Compared with usual care, telemedicine-delivered CC interventions improved HbA1c and time in range but did not significantly impact other clinically relevant outcomes in patients with T1DM. High-quality, large-scale RCTs are needed to draw definitive conclusions. These findings provide health care professionals with updated evidence on the role of telemedicine in glycemic control for patients with T1DM. CLINICALTRIAL PROSPERO CRD42024523025; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024523025
- Open Access
- 3 November 2022
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 247, 114270
miR-3614–5p downregulation promotes cadmium-induced breast cancer cell proliferation and metastasis by targeting TXNRD1
- 3 November 2022
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 247, 114270
Open AccessmiR-3614–5p downregulation promotes cadmium-induced breast cancer cell proliferation and metastasis by targeting TXNRD1
- 1 January 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 193 (1) , 435-441
Is radical mediastinal lymphadenectomy necessary for elderly patients with clinical N-negative non–small-cell lung cancer? A single center matched-pair study
- 1 January 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 193 (1) , 435-441
Is radical mediastinal lymphadenectomy necessary for elderly patients with clinical N-negative non–small-cell lung cancer? A single center matched-pair study